214 related articles for article (PubMed ID: 28728494)
1. The clinical significance of QT prolongation associated with tamoxifen: A review of the literature.
Fung K; Imeson J; Cusano F
J Oncol Pharm Pract; 2018 Oct; 24(7):525-530. PubMed ID: 28728494
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitor-associated QT interval prolongation.
Hunt K; Hughes CA; Hills-Nieminen C
Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
4. What clinicians should know about the QT interval.
Al-Khatib SM; LaPointe NM; Kramer JM; Califf RM
JAMA; 2003 Apr 23-30; 289(16):2120-7. PubMed ID: 12709470
[TBL] [Abstract][Full Text] [Related]
5. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
Khan Q; Ismail M; Haider I
Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin-induced proarrhythmia and cardiovascular death.
Howard PA
Ann Pharmacother; 2013 Nov; 47(11):1547-51. PubMed ID: 24285766
[TBL] [Abstract][Full Text] [Related]
8. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
Khan Q; Ismail M; Khan S
BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
[TBL] [Abstract][Full Text] [Related]
9. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
10. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
11. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
13. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
14. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
de Lemos ML; Kung C; Kletas V; Badry N; Kang I
J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance and management of drug-related QT interval prolongation.
Crouch MA; Limon L; Cassano AT
Pharmacotherapy; 2003 Jul; 23(7):881-908. PubMed ID: 12885102
[TBL] [Abstract][Full Text] [Related]
16. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
17. Citalopram, QTc Prolongation, and Torsades de Pointes.
Tampi RR; Balderas M; Carter KV; Tampi DJ; Moca M; Knudsen A; May J
Psychosomatics; 2015; 56(1):36-43. PubMed ID: 25619672
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
Vieweg WV; Wood MA
Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
[TBL] [Abstract][Full Text] [Related]
19. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial agents-associated with QT interval prolongation.
Bril F; Gonzalez CD; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):85-92. PubMed ID: 20210724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
